Findings

What do systematic reviews say?

3 questions · 5 findings · 2 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Vitamin K antagonists vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 0.33 [0.01, 8.1]
1 study · 439 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 2 [0.18, 21.9]
1 study · 440 participants
Very low

Vitamin D vs placebo or usual care

Death at hospital discharge · individuals with moderate to severe disease

1 finding from 1 review

Vitamin D supplementation for the treatment of COVID‐19: a living systematic review 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 313 participants
Very low

Aspirin vs vitamin K antagonist (VKA)

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 3 [0.12, 73.24]
1 study · 440 participants
Very low
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.47]
1 study · 440 participants
Very low